Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus trametinib in metastatic KRAS-mutant non-small cell lung cancer
NL-OMON46994Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib and trametinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Incidence of dose-limiting toxicities and Progression-free survival. Started Oct 2014; status: active, not recruiting.
02
Drugs
lapatinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON46994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46994.